Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

Grothey, Axel; Sobrero, Alberto; F. Shields, Anthony; Yoshino, Takayuki; Paul, James; Taı̈eb, Julien; Souglakos, John; Shi, Qian; Kerr, Rachel; Labianca, Roberto; A. Meyerhardt, Jeffrey; Vernerey, Déwi; Yamanaka, Takeharu; Boukovinas, Ioannis; P. Meyers, Jeffrey; A. Renfro, Lindsay; Niedzwiecki, Donna; Watanabe, Toshiaki; Torri, Valter; Saunders, Mark; J. Sargent, Daniel; André, Thierry; Iveson, Timothy

doi:10.1056/nejmoa1713709

Public

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

Published in New England Journal of Medicine • Mar 28, 2018

Authors:

Axel Grothey

Alberto Sobrero

Anthony F. Shields

Abstract

BACKGROUND: Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer. However, since oxaliplatin is associated with cumulative neurotoxicity, a shorter duration of therapy could spare toxic effe...

Subject

Oxaliplatin

Medicine

Regimen

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!